The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
about
Human steroid biosynthesis for the oncologist17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol productionRelationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptorThe androgen receptor governs the execution, but not programming, of male sexual and territorial behaviorsEfavirenz directly modulates the oestrogen receptor and induces breast cancer cell growthDHEA metabolites activate estrogen receptors alpha and betaThe molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?Multiple roles of COUP-TFII in cancer initiation and progressionSynergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.Human 3β-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations.An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.Cooperative Dynamics of AR and ER Activity in Breast Cancer.Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy.Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability.Post-menopausal breast cancer: from estrogen to androgen receptor.High N-acetyltransferase 1 (NAT1) expression is associated with estrogen receptor expression in breast tumors, but is not under direct regulation by estradiol, 17beta-diol, or dihydrotestosterone in breast cancer cells.Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients
P2860
Q26999384-F62F1AC4-0869-409C-AE68-86674BB655C8Q27659972-53CCB0EB-75D9-4AF8-9A6B-5EFCD301ADCBQ33710960-7354BC8F-4DC8-4985-B9ED-19E7B54C7A77Q33728381-AA269F37-7F3A-4DF1-A58E-0204D0F9A8AAQ33820667-2E7B4E93-E50C-4222-A3C5-4F358294FD0DQ34073195-925D7F26-4A6D-45FB-BB32-0AD426B07D0FQ34143084-F2AC081E-A047-46A9-BAFC-B4206F2318FAQ34309799-7FC6D9CE-EC6C-4381-9AD0-CBCC3A798E3EQ34311300-6310D1B0-2209-42D4-A0AB-3E51B5A0F591Q34522279-ACCA2700-3441-4208-9125-AAC02045AF37Q36113793-7877A201-2789-4180-A2A7-0E846770D787Q36312989-A9D2D9C0-ADF3-4F3D-8256-A9DD2BC134D2Q36331426-1A3FFB39-DDE2-4B63-B0FA-46FA7F721790Q36578211-25D1BC91-2838-455C-A654-6E654578C609Q36880048-A8761A4D-2D41-4AF7-B6B1-8723FFC29655Q36892987-C7BF1DCF-FCA4-4AA2-BA0D-C7086CF2B9BFQ37292419-56FEBA3E-6ECB-4391-AAC9-8ADCE88E9DC8Q37633691-7BDC3EA5-8A01-43E5-B604-3E782E514D7CQ38749913-BD5975C0-2C2C-4496-A40B-A13D2E8A694AQ39005392-66A80C00-19ED-476E-9D54-B1EF0FB37490Q39227889-116995A1-6921-494A-A253-E6DD2ACAAC38Q39558942-AE8BB00D-AE2F-4C11-B0FF-52237B00B2DFQ47094109-8BCD3999-7B0C-4C86-93B8-9EE9C647B29EQ48232407-7644AB29-CD02-467E-9869-01868107274DQ50467757-BD16D4E9-BE79-4556-9FBB-8CBAD9BBEEDBQ50478764-84960058-55BA-4F44-81BE-58D03B31C458Q58333416-3D811F83-4E72-403D-A613-3957C66D079A
P2860
The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The androgen metabolite 5alpha ...... aromatase inhibitor resistance
@en
The androgen metabolite 5alpha ...... romatase inhibitor resistance.
@nl
type
label
The androgen metabolite 5alpha ...... aromatase inhibitor resistance
@en
The androgen metabolite 5alpha ...... romatase inhibitor resistance.
@nl
prefLabel
The androgen metabolite 5alpha ...... aromatase inhibitor resistance
@en
The androgen metabolite 5alpha ...... romatase inhibitor resistance.
@nl
P2093
P2860
P1476
The androgen metabolite 5alpha ...... aromatase inhibitor resistance
@en
P2093
James M Rae
Jose M Larios
Kevin E Cordero
Marc E Lippman
Matthew J Sikora
Michael D Johnson
P2860
P2888
P304
P356
10.1007/S10549-008-0080-8
P407
P577
2008-06-04T00:00:00Z